Valneva heads into its third-quarter report with two very different stories running side by side. The long-term case now rests almost entirely on Pfizer's Lyme disease vaccine, which took a meaningful step forward when Pfizer filed for European approval. The near-term case rests on a commercial vaccine business that shrank sharply in the first half and absorbed a string of costly one-time charges. This report is mostly about the second story, and whether the operating business can stop bleeding while the company waits on regulators.
The Street expects a loss of $0.23 per share on revenue of about $42.0 million. That would mark roughly 22% revenue growth from the $34.4 million reported a year ago and a far narrower loss than the $0.61 per share lost in the same quarter of 2025. It would also be a modest sequential improvement from last quarter's $40.6 million in revenue and $0.40 loss. On paper that looks like recovery. The more useful test is the full-year math. Management cut its 2026 product sales outlook to €135 million to €150 million after the first quarter and only reaffirmed it last time. With first-half product sales at €64 million, Valneva needs roughly €71 million to €86 million in the back half, or about €35 million to €43 million a quarter. A third quarter that lands near the bottom of that pace would leave little room for error in the fourth quarter and would invite another guidance trim.
The biggest swing factor is Ixiaro, the Japanese encephalitis vaccine. First-half sales were hurt by the timing of U.S. Department of Defense orders, with a new contract still unsigned at the last update and expected in the second half. A signed contract, or clear evidence of resumed military shipments, would go a long way toward validating management's reaffirmed range. Continued delay would challenge it directly. Weak travel demand tied to geopolitical uncertainty, the German distributor transition and the regulatory problems at the Almeda facility, which leave U.S. Ixiaro supply dependent on the older Menson site, are the other pressure points on both Ixiaro and Ducoral.
Margins deserve equal attention. Ixiaro gross margin fell to 56.4% from 65.5%, Ducoral's dropped to 24.7% from 52.9%, and the chikungunya vaccine Ixchiq ran at a negative margin after a €9.7 million cancellation provision and a €4.5 million inventory write-down. If those charges were truly one-offs, gross margins should rebound noticeably this quarter. The June restructuring, which cut 10% to 15% of the workforce, consolidated research in Vienna and set up the roughly €6 million sale of the Nantes site, should also begin showing up in lower operating expenses. Investors will want to see cash, which stood at €121.5 million after an equity raise, holding up without fresh financing.
Sentiment has thawed somewhat, with bearish readings easing to about 62% from 82% ahead of the last report. The stock is up about 2% since then while the S&P 500 fell 5.5%, a respectable showing driven largely by the Lyme filing. Still, at $5.57 it sits near the low end of its post-earnings range of $5.25 to $7.31, having given back most of the enthusiasm. Secondary items such as progress toward the 100,000-person Brazil chikungunya pilot, early Butantan drug-substance revenue and timing on Shigella readouts add texture but are unlikely to move the needle alone.
The central question is whether Valneva can show that its commercial business has bottomed. Management now ties financial self-sustainability to 2027 and to Lyme approval, but a credible bridge to that point requires the reaffirmed sales range to hold and margins to recover. Deliver both, and the Lyme optionality looks well funded. Miss on either, and the stock becomes an even more binary wager on Pfizer's regulators.